The results from the MONARCH 3 trial stated that the combined use of abemaciclib together with a non-steroidal AI as initial therapy in postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer was associated with improved progression-free survival compared to use of AIs alone. Here, ERBB2 is linked to breast carcinoma.